BCIQ Profiles

Company Profile Report
0119 Gritstone covid
BioCentury & Getty Images

Product Development

Gritstone sending a mixed-modality COVID vaccine to Phase I

The regimen is optimized to induce strong T cell responses as well as strong antibody responses

Jan 20, 2021 | 3:00 AM GMT

NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody responses.

Read the full 691 word article

How to gain access

Continue reading with a
two-week free trial.